Patent · US Active

Therapeutic compounds

US9181544B2 · kind B2 · utility

3Cited by
18References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 13, 2012
Grant dateNov 10, 2015
Priority date
Expiry dateFeb 13, 2032

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2750/14143
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention is directed to RNA interference (RNAi) molecules targeted against a Huntington's disease nucleic acid sequence, and methods of using these RNAi molecules to treat Huntington's disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.